We have updated our privacy policy to make it clearer how we use your personal information

News 11 February 2021
| Original story from UCL

The results of the large-scale international study published in the New England Journal for Medicine are known as the “Game Changer” to improve the health of people with obesity and could play an important role in helping the UK reduce the effects of diseases such as COVID-19, the drug semaglutide hijacks the body’s appetite control system in the brain, leading to a decrease in hunger and caloric intake by Rachel Batterham, professor of obesity, diabetes, and endocrinology who directs the UCL Obesity Research Center and UCLH Weight Management Center, is a lead author on the paper, which is nearly 2000 people in 16 countries involved Professor Batterham (UCL Medicine) said, “The results of this study represent a major breakthrough in improving the health of people with obesity. Three quarters (75%) of people who received Semaglutide 2 lost more than 4 mg 10% of their body weight and more than a third more than 20% No other drug has come close to this weight loss This really is a game changer, for the first time people can do through medication what only weight loss surgery could doProfessor Batterham added: The health effects of obesity have been brought to the fore by COVID-19, where obesity is the risk at which Virus dying significantly increases and increases the risk of many life-limiting serious diseases such as heart disease, type 2 diabetes, liver disease and certain types of cancer.This drug could have a significant impact on UK health policy in the years to come, with the average participant in the study losing 153 kg (almost 3 stone); This was accompanied by a reduction in risk factors for heart disease and diabetes such as waist circumference, blood lipids, blood sugar and blood pressure, and reported improvements in their general quality of life Treatment of obesity”Semaglutide has already been approved and is used clinically at a lower dose to treat diabetes Hence, as doctors, we are already familiar with its use.For me, this is particularly exciting as I was involved in very early studies on GLP1 (when I was working at Hammersmith Hospital in the 1990s, we were the first to show in laboratory studies that GLP1 did Appetite Affected) so it is good to see this translated into an effective treatment for people with obesity With evidence from this study, semaglutide has been approved for regulatory approval for the treatment of obesity by the National Institute of Clinical Excellence (NICE), the European Medicines Agency ( EMA) and the US Food and Drug Administration (FDA) submitted) About the study In the randomized controlled phase III study “STEP” * 1961 adults participated who were either overweight or overweight (mean weight 105 kg / 16) 5 stone; Body Mass Index 38 kg / m2) and took place at 129 locations in 16 countries in Asia, Europe, North America and South America Participants took a 24 mg semaglutide (or a matching placebo) weekly by subcutaneous injection (under the skin); Similar to People With Diabetes Injecting Insulin A total of 943% of participants completed the 68-week study, which began in Fall 2018 Participants also received one-on-one face-to-face or telephone counseling from registered dietitians every four weeks about adhering to the low-calorie diet and increased physical activity and guidance to provide behavioral strategies and motivation In addition, participants were given incentives such as kettle bells or food scales to mark progress and milestones.Those who took semaglutide, the average weight loss was 153 kg (almost three stones) with a reduction in BMI of – 554 The placebo group saw an average weight loss of 26 kg (04 Stein) with a reduction in BMI of -092 Those who took semaglutide also saw a reduction in risk factors for heart disease and diabetes such as waist circumference, blood lipids, blood sugar, and blood pressure, and have reported improvements in their overall quality of life About the drug Semaglutide is clinically approved for use in patients with type 2 diabetes but is usually prescribed in much lower doses of 1 mg The drug has a compound which is structurally similar to (and mimics) the human glucagon-like peptide-1 (GLP-1) hormone and is released from the intestine into the blood after meals. GLP-1 induces weight loss by reducing hunger, increasing feelings of fullness, and thereby helping people eat less and reduce their caloric intake.While the STEP study has gone through Phase I and II studies, the 2 has been rated For safety reasons, some participants in the Phase III study reported side effects of the drug, including mild to Moderate nausea and diarrhea that were temporary and generally These were resolved without permanent termination of the study Reference: Wilding JPH, Batterham RL, Calanna S et al Semaglutide once a week in overweight or obese adults New Eng J Med 2021 doi: 101056 / NEJMoa2032183 This article has been republished from the following materials Note: The material may have been edited for length and content.For more information, please refer to the indicated source

GIP Receptor: A Novel Therapeutic Target to Combat Obesity?

The GIP receptor in the central nervous system plays a critical role in regulating body weight and food intake New research suggests that the GIP receptor could be a potential therapeutic target for obesity and type 2 diabetes

Greater involvement of pregnant people in COVID-19 vaccine research is needed

Longstanding barriers to including pregnant and breastfeeding people in clinical research have resulted in this population now deciding whether or not to receive a SARS-CoV-2 vaccine without scientific evidence, say scientists

Researchers reveal how the cancer drug rituximab works

The first therapeutic antibody to be approved against B tumor cells was rituximab, a cancer drug against the membrane protein CD20. Now a team of immunologists has solved the mystery of how it works

Log in or subscribe for free to personalize the content you see on the Technology Networks home page


World News – UK – Treatment of Obesity: Semaglutide is said to reduce body weight by 20% in global clinical trial

Source: https://www.technologynetworks.com/drug-discovery/news/treating-obesity-semaglutide-shown-to-cut-body-weight-by-20-in-global-clinical-trial-345452